Solcoseril (protein-free haemodialysate from calf blood) solution for injections 5 ml. 42.5 mg/ml. vials №5

Description

Solcoseril (protein-free haemodialysate from calf blood) solution for injections 5 ml. 42.5 mg/ml. vials №5

Composition

active ingredient: protein-free haemodialysate from calf blood;

1 ml solution for injection contains deproteinized hemoderivate from the blood of calves (Bos Taurus), chemically and biologically standardized, in terms of dry matter 42.5 mg;

excipients: hydrochloric acid solution 25%, sodium hydroxide solution 27%, water for injection.

Dosage form

Injection.

Basic physical and chemical properties: transparent solution from yellowish to yellow.

Pharmacological group

Other medicines.
ATX Code V03AX.

Pharmacological properties

Solcoseril is a deproteinized hemoderivative from calf blood, obtained by dialysis and ultrafiltration, containing a wide range of natural low molecular weight substances with a molecular weight of 5000 Da, and only some of them are described chemically and pharmacologically.

In in vitro tests, as well as during preclinical and clinical studies, it was found that Solcoseryl:

• supports aerobic metabolism and oxidative phosphorylation, therefore, contributes to the supply of high-energy phosphates to undernourished cells;
• increases (in vitro) the use of oxygen and the supply of glucose to tissues and cells suffering from hypoxia and metabolically depleted;
• improves the processes of repair and regeneration of damaged tissues and / or tissues limited in sufficient amounts of nutrients;
• prevents or reduces secondary degeneration and pathological changes in reversibly damaged cellular systems;
• accelerates collagen synthesis in in vitro models;
• stimulates cell proliferation and movement in vitro.

Thus, the drug protects tissues in a state of hypoxia and nutritional deficiency, promotes tissue regeneration, accelerates and improves wound healing.

Indications:

• Occlusive peripheral arterial disease (OPAD) in stages III-IV in patients who are contraindicated in the use of other vasoactive drugs or who are intolerant to them;
• Chronic venous insufficiency with treatment-resistant leg ulcers.

Contraindications

Solcoseril has no contraindications, but when using eye gel, it is still better to refrain from driving.

Application during pregnancy and lactation

In medicine, there is no data on the teratogenic effects of Solcoseryl, however, when using the drug during lactation, it is recommended to stop breastfeeding.

Method of administration and dosage

If the patient’s clinical condition permits, Solcoseril solution should be used as an intravenous infusion rather than as an intravenous injection. The drug should be used as an intravenous bolus injection.

When used in the form of infusions or injections, the drug should be diluted in a ratio of at least 1: 1 with isotonic sodium chloride solution or 5% glucose solution or a mixture of glucose and sodium chloride solutions. The solution should be injected slowly. The drug should not be diluted with infusion solutions containing potassium.

Infusions

If possible, the drug should be used as an intravenous infusion, especially when the total volume of the diluted solution is more than 40 ml. The rate of infusion depends on the hemodynamic state of the patient.

Injections

If it is necessary to administer the drug as an injection, the solution should be administered slowly over at least 2 minutes in order to reduce the possibility of a rapid increase in the level of potassium in the blood. The volume of the diluted solution should not exceed 40 ml.

Recommended dosage:

• occlusive peripheral arterial disease (Fontaine stages III-IV): Solcoseril 850 mg (corresponding to 20 ml of undiluted injection) daily intravenously. Usually the duration of use is up to 4 weeks and depends on the clinical picture;
• chronic venous insufficiency with persistent trophic ulcers of the legs: 425 mg Solcoseril (corresponding to 10 ml of undiluted injection solution) intravenously 3 times a week. Usually the duration of use is 4 weeks and depends on the course of the disease. As an essential supportive measure for edema, a compression bandage (bandage) is prescribed.

Children

There is no experience of use in children and adolescents (under 18 years of age). The safety of the drug in pediatric patients has not been studied.

Overdose

There are no data on overdose of any dosage form of Solcoseril.

Side effects

Very rarely, with injection treatment with Solcoseril, allergic reactions such as urticaria may occur. With local application of Solcoseril solution, marginal dermatitis and curettage may occur. In both cases, it is recommended to urgently stop the administration of the drug and prescribe appropriate symptomatic treatment.